Form 4: Biocon Ltd and Biocon Pharma Inc. Report Beneficial Ownership Changes in Bicara Therapeutics Inc. Following IPO

Biocon Ltd and Biocon Pharma Inc. report changes in their beneficial ownership of Bicara Therapeutics Inc. common stock following the conversion of preferred stock in connection with the company's initial public offering.

Summary

• Biocon Ltd and Biocon Pharma Inc., both reporting persons, filed a Form 4 to report changes in their beneficial ownership of Bicara Therapeutics Inc. (BCAX) common stock.
• The changes occurred on September 16, 2024, due to the automatic conversion of Series Seed Redeemable Convertible Preferred Stock into common stock upon the closing of Bicara Therapeutics' initial public offering (IPO).
• Biocon Ltd. acquired 4,327,365 shares of common stock through the conversion and now indirectly owns 4,443,122 shares.
• Biocon Pharma Inc. acquired 1,080,775 shares of common stock through the conversion and now indirectly owns 1,080,775 shares.
• The conversion ratio was 9.2435-to-one, meaning each share of preferred stock converted into 9.2435 shares of common stock.
• Kiran Mazumdar-Shaw is the managing member of both Biocon Ltd. and Biocon Pharma Inc., and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing related to an IPO. The sentiment is neutral to slightly positive as it reflects the completion of a planned corporate action.

Positives

• The conversion of preferred stock to common stock simplifies Bicara Therapeutics' capital structure following its IPO.
• Biocon Ltd and Biocon Pharma Inc. maintain a significant ownership stake in Bicara Therapeutics.

Management Comments

• Kiran Mazumdar-Shaw disclaims beneficial ownership of the shares held by Biocon Ltd. and Biocon Pharma Inc. except to the extent of her pecuniary interest.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders of publicly traded companies, providing transparency to the market.

Stakeholder Impact

• The conversion of preferred stock to common stock may have a minor impact on shareholders by slightly diluting ownership.

Key Dates